On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. 5 years ago Research & Clinical Trial Webinars,Webinars You may also like 47:43 Webinar: Capricor Therapeutics – Update on Deramiocel for Cardiomyopathy in Patients with Duchenne 9 months ago Research & Clinical Trial Webinars,Webinars cap-1002,capricor,cardiac,deramiocel 02:15:11 PPMD’s Duchenne Early Intervention Symposium 9 months ago Webinars newborn screening 01:08:05 Webinar: Solid Biosciences – Update on Gene Therapy Candidate SGT-003 9 months ago Research & Clinical Trial Webinars,Webinars gene therapy,sgt-003,solid biosciences 58:14 Webinar: Sevasemten – CANYON Trial Topline Results 12 months ago Research & Clinical Trial Webinars,Webinars edg-5506,edgewise 1:01:40 Webinar: RGX-202 – AFFINITY DUCHENNE Pivotal Program and Functional Data 1 year ago Research & Clinical Trial Webinars,Webinars gene therapy,RGX-202 51:49 Webinar: INSPIRE DUCHENNE Clinical Trial Update and Study Expansion 1 year ago Research & Clinical Trial Webinars,Webinars sgt-003,solid biosciences 56:19 Webinar: Exploring Muscle Regeneration – A New Approach with Satellos 1 year ago Research & Clinical Trial Webinars,Webinars 44:01 World Muscle Society 2024: CIFFREO Data Discussion with Pfizer 1 year ago Research & Clinical Trial Webinars,Webinars fordadistrogene movaparvovec,pfizer «12345…28»Page 3 of 28